Ca\textsubscript{v}1.3 L-type Ca\textsuperscript{2+} channels mediate long-term adaptation in dopamine D2L-mediated GluA1 trafficking in the dorsal striatum following cocaine exposure

Kathryn Schierberl, Thomas Giordano, Shirish Satpute, Jin Hao, Gagandeep Kaur, Franz Hofmann, Sven Moosmang, Joerg Striessnig and Anjali Rajadhyaksha

1 Graduate Program in Neuroscience; Weill Cornell Medical College; New York, NY USA; 2 Martinos Center for Biomedical Engineering; Massachusetts General Hospital; Harvard Medical School; Charlestown, MA USA; 3 Department of Pediatrics; Division of Pediatric Neurology; Weill Cornell Medical College; New York, NY USA; 4 Research Group 923; Technical University Munich; Munich, Germany; 5 Institute for Pharmacology; Technical University Munich; Munich, Germany; 6 Institute of Pharmacy, Pharmacology and Toxicology; University of Innsbruck; Innsbruck, Austria

Keywords: cocaine, dorsal striatum, VTA, GluA1, Cav1.3, dopamine D2, ERK, CREB, DARPP-32, Akt, GSK3β

Introduction

Repeated exposure to cocaine results in long-lasting changes in dopaminergic and glutamatergic signaling in brain reward regions including the dorsal striatum (dStr), which has been implicated in persistent cocaine-induced behavioral responses; however, the precise mechanism underlying these changes remains unknown. Utilizing cocaine psychomotor sensitization in mice we find that repeated cocaine results in a basal reduction of Ser 845 GluA1 and cell surface GluA1 levels in the dorsal striatum (dStr) following a protracted withdrawal period, an adaptation that is dependent on Cav 1.3 channels but not those expressed in the VTA. We find that the basally-induced decrease in this phosphoprotein is the result of recruitment of the striatal dopamine D2 pathway, as evidenced by enhanced levels of D2 receptor (D2R) mRNA expression and D2R function as examined using the D2R antagonist, eticlopride, as well as alterations in the phosphorylation status of several downstream molecular targets of D2R’s, including CREB, DARPP-32, Akt and GSK3β. Taken together with our recently published findings examining similar phenomena in the nucleus accumbens (NAc), these results underscore the utilization of divergent molecular mechanisms in the dStr, in mediating cocaine-induced persistent behavioral changes.
phosphorylation and cell surface levels in the dStr. We demonstrate that as opposed to a D1/Ca\textsubscript{v}1.2 mechanism that regulates cocaine-induced phosphorylation and trafficking of GluA1 in the NAc,\textsuperscript{11} in the dStr Ca\textsubscript{v}1.3 channels recruit the D2R pathway that regulates GluA1 phosphorylation and cell surface levels.

**Results and Discussion**

Repeated cocaine exposure results in lower levels of Ser\textsubscript{845} P-GluA1 phosphorylation and cell surface GluA1 levels in the dorsal striatum following 21 d of withdrawal, an adaptation dependent on Ca\textsubscript{v}1.3 channels. To evaluate levels of Ser\textsubscript{845} and Ser\textsubscript{849} GluA1 phosphorylation (western blot analysis as previously described in Schierberl et al.\textsuperscript{11}) in Ca\textsubscript{v}1.3 KO mice (significant interaction, treatment group x withdrawal day, F\textsubscript{1,70} = 67.43; p < 0.0001). Our finding of lower basal cell surface GluA1 is in contrast to that observed by Ferrario et al.,\textsuperscript{6} who report no change in GluA1 cell surface levels in the dStr of rats challenged 21 d later with saline or cocaine. We found that cocaine pre-exposure resulted in significantly lower basal levels of Ser\textsubscript{845} P-GluA1 (Fig. 1A, WT: coc-sal vs. sal-sal; Fig. 1B, WT: coc-coc vs. sal-sal) in Ca\textsubscript{v}1.3 WT mice when examined 21 d following the last cocaine treatment, a change that was absent in Ca\textsubscript{v}1.3 KO mice (significant interaction, treatment group x genotype, F\textsubscript{1,70} = 67.43; p < 0.0001; surface GluA1: F\textsubscript{3,60} = 37.83; p < 0.0001). Our finding of lower basal cell surface GluA1 is consistent with that observed by Ferrario et al.,\textsuperscript{6} who showed no change in GluA1 cell surface levels in the dStr of rats following cocaine withdrawal from a sensitizing regimen of cocaine. We found that a cocaine challenge further lowered the levels of Ser\textsubscript{845} P-GluA1 (Fig. 1A, WT: coc-sal vs. sal-sal) and surface GluA1 in WT mice (Fig. 1B, WT: coc-coc vs. sal-sal) compared with saline challenged mice; however, the differences did not reach significance. Both these changes were absent in Ca\textsubscript{v}1.3 KO mice (Fig. 1A and B, KO: coc-sal vs. coc-sal). Our findings of a decrease in cell surface GluA1 levels following a cocaine challenge in WT mice are also in disagreement with those of Ferrario et al. (2010)\textsuperscript{10} in that they show that GluA1 cell surface levels in cocaine pre-exposed rats challenged with saline and cocaine are indistinguishable from each other both 30 min and 24 h after challenge. However, their challenge injections were administered on withdrawal day 14 as opposed to day 21 and their studies were conducted in rats vs. mice. An acute cocaine injection increased Ser\textsubscript{845} P-GluA1 levels in Ca\textsubscript{v}1.3 WT mice, as has been previously demonstrated,\textsuperscript{11},\textsuperscript{12} a change that was also observed in KO mice (Fig. 1A, WT and KO: sal-sal vs. sal-sal). Acute cocaine treatment also increased cell surface levels of GluA1 in Ca\textsubscript{v}1.3 WT and KO mice (Fig. 1B, WT and KO: sal-sal vs. sal-sal) demonstrating no role for Ca\textsubscript{v}1.3 channels in regulating GluA1 following acute cocaine treatment. Ser\textsubscript{831} P-GluA1 was unaltered in the dStr following cocaine pre-exposure or cocaine challenge (data not shown) and no change in GluA2 cell surface levels was observed (data not shown), consistent with Ferrario et al.\textsuperscript{6} The above findings were further confirmed in Ca\textsubscript{v}1.2 dihydropyridine (DHP)-insensitive mutant mice (Fig. 1C). In this mutant mouse line treatment with the L-Type blocker nifedipine specifically blocks only Ca\textsubscript{v}1.3 channels.\textsuperscript{13,\textsuperscript{14}} This circumvents any developmental compensatory mechanisms that may have occurred in constitutive Ca\textsubscript{v}1.3 KO mice. Consistent with our Ca\textsubscript{v}1.3 KO data, systemic injection of nifedipine (25 mg/kg i.p.), prior to each cocaine injection (15 mg/kg i.p., once a day for 5 d), blocked the decrease in Ser\textsubscript{845} P-GluA1 (Fig. 1C, nif-coc vs. veh-coc) and surface GluA1 (Fig. 1D, nif-coc vs. veh-coc) in the dStr when examined 21 d later. To examine the role of Ca\textsubscript{v}1.2 channels in GluA1 phosphorylation in the dStr we utilized CNS-specific Ca\textsubscript{v}1.2 KO mice (Ca\textsubscript{v}1.2\textsuperscript{K0} KO mice). We found no role of Ca\textsubscript{v}1.2 channels in regulating Ser\textsubscript{845} P-GluA1. Cocaine pre-exposed Ca\textsubscript{v}1.3 WT (WT: coc-sal vs. sal-sal) and Ca\textsubscript{v}1.2 KO (KO: coc-sal vs. sal-sal) mice exhibited significantly lower levels of Ser\textsubscript{845} P-GluA1 (Fig. 1E). These findings demonstrate that the decrease in Ser\textsubscript{845} P-GluA1 and surface GluA1 in the dStr following extended withdrawal from cocaine treatment are dependent on Ca\textsubscript{v}1.3 and not Ca\textsubscript{v}1.2 channels.

We have recently shown that changes in GluA1 phosphorylation in the NAc following extended withdrawal are dependent on Ca\textsubscript{v}1.3 channels in the VTA during the development of cocaine sensitization.\textsuperscript{11} Thus, we next evaluated if VTA Ca\textsubscript{v}1.3 channels are also necessary for the decrease in Ser\textsubscript{845} P-GluA1 in the dStr (Fig. 1F). We additionally examined the role of ERK2 in the VTA (Fig. 1G), a downstream target of Ca\textsubscript{v}1.3 channels.\textsuperscript{11} Recombinant adenosineviral vector (rAAV) expressing Ca\textsubscript{v}1.3 siRNA or control siRNA was stereotaxically delivered bilaterally into the VTA three weeks before the start of the cocaine sensitization regimen [see detailed methods in Schierberl et al. (2011)].\textsuperscript{11} Twenty-one days following the last cocaine sensitization treatment, dStr tissue was examined for Ser\textsubscript{845} P-GluA1 levels. We found that VTA Ca\textsubscript{v}1.3 plays no role in regulating Ser\textsubscript{845} P-GluA1 levels in the dStr. Ser\textsubscript{845} P-GluA1 levels did not differ between control siRNA and Ca\textsubscript{v}1.3 siRNA injected mice (Fig. 1F). Similarly, stereotaxic delivery of a rAAV-expressing ERK2 siRNA (described in Schierberl et al.)\textsuperscript{11} had no effect on Ser\textsubscript{845} P-GluA1 levels (Fig. 1G). This lack of a role for VTA Ca\textsubscript{v}1.3 channels in mediating GluA1 adaptations observed in the dStr following extended withdrawal is not surprising as VTA neurons project primarily to the NAc,\textsuperscript{17} a pathway implicated in the initial stages of drug taking, whereas the substantia nigra to dStr pathway has been implicated in the more compulsive aspects of addictive behavior.\textsuperscript{18}

Lower Ser\textsubscript{845} P-GluA1 phosphorylation in the dorsal striatum following withdrawal from cocaine is a result of enhanced dopamine D2R signaling. As dopamine D2 receptors have been shown to regulate Ser\textsubscript{845} P-GluA1 in the dStr\textsuperscript{11,\textsuperscript{19}} and we have previously shown that repeated treatment with the psychomotor stimulant amphetamine increases the D2R long-splice variant (D2L) mRNA in the dStr via a Cav1.3-dependent mechanism,\textsuperscript{11} we next tested the hypothesis that repeated cocaine enhances D2L-mediated signaling that results in the lower Ser\textsubscript{845} P-GluA1 we observe. We measured D2L mRNA levels (Fig. 2A), in addition to mRNA levels of dopamine D1, D2S, and D3 in the striatum of Ca\textsubscript{v}1.3 WT and KO mice 21 d following repeated cocaine...
Figure 1. Repeated cocaine decreases S845 P-GluA1 and GluA1 cell surface levels in the dorsal striatum following 21 d of withdrawal, an adaptation dependent on Ca\textsubscript{v}1.3 channels. (A and B) Cocaine pre-exposed Ca\textsubscript{v}1.3 WT but not Ca\textsubscript{v}1.3 KO mice had significantly lower levels of S845 P-GluA1 (A) and surface (S)/intracellular (I) GluA1 (B) in the dorsal striatum (dStr) when examined 21 d following withdrawal from cocaine. Acute treatment with cocaine (sal-coc) significantly increased both S845 P-GluA1 and S/I GluA1 in Ca\textsubscript{v}1.3 WT and KO mice. n = 8–12/treatment. (C and D) Vehicle pretreated Ca\textsubscript{v}1.2 DHP\textsuperscript{2}/\textsuperscript{2} mice had significantly lower levels of S845 P-GluA1 (C) and S/I GluA1 (D) compared with saline controls (sal-sal) when examined 21 d following withdrawal from cocaine. Nifedipine pretreatment (nif-coc) blocked this decrease in S845 P-GluA1. n = 8–12/treatment. (E) Knockout of Ca\textsubscript{v}1.2 had no effect on S845 P-GluA1 levels. Cocaine pre-exposed Ca\textsubscript{v}1.2 CNS WT and Ca\textsubscript{v}1.2 CNS KO mice exhibited significantly lower levels of S845 P-GluA1 compared with saline control mice (dashed line). n = 5–7/group. (F and G) Intra-VTA stereotaxic delivery of Ca\textsubscript{v}1.3 siRNA (F) or ERK2 siRNA (G) and their respective controls had significantly lower levels of S845 P-GluA1 compared with saline control mice (dashed line). n = 12–14/treatment. *p < 0.05, vs. sal-sal, sal, coc, cocaine. Data represent the mean ± SEM.
treatment using quantitative real time PCR (qPCR) and receptor-specific primers (Fig. 2A). We found significantly higher levels of D2L mRNA in the dStr of cocaine pre-exposed Cav1.3 WT but not Cav1.3 KO mice (Fig. 2A, significant interaction, treatment x genotype, $F_{1,32} = 100.3; p < 0.0001$). D2L levels were not altered in the NAc nor were D1 (WT, sal, 100 ± 5 vs. coc, 102 ± 4; D2S, WT, sal, 100 ± 5 vs. coc, 102 ± 4; D3, WT, sal, 100 ± 4 vs. coc, 97 ± 3; D3, WT, sal, 100 ± 4 vs. coc, 105 ± 5).

**Figure 2.** Repeated cocaine exposure recruits the dopamine D2L pathway in the dorsal striatum following extended withdrawal. (A) Repeated cocaine significantly increased D2L mRNA levels in the dStr of Cav1.3 WT but not Cav1.3 KO mice. No change was seen in the NAc; **$p < 0.01$, $n = 8–9/treatment.** (B) DStr D2L mRNA levels correlated with expression of sensitization. $n = 9$, $r = 0.68$, $p < 0.01$, Pearson correlation. (C and D) Knockdown of VTA Cav1.3 or VTA ERK2 had no effect on the increase in D2L mRNA in the dStr. Both VTA Cav1.3 siRNA and ERK2 siRNA injected mice had significantly higher levels of D2L mRNA compared with saline controls (dashed line; **$p < 0.01$, $n = 12–14/treatment.** (E) Eticlopride (etic; 0.2 mg/kg i.p.) significantly increased S845 P-GluA1 in the dStr of cocaine pre-exposed mice compared with saline pre-exposed mice. **$p < 0.05$, coc-etic vs. sal-etic.** *$p < 0.05$ vs. sal-sal. (F) Eticlopride increased S845 P-GluA1 in the NAc to the same extent in saline- and cocaine-pre-exposed mice (coc-etic vs. sal-etic). **$p < 0.05$ vs. sal-sal. $n = 10–14/treatment. Data represent the mean ± SEM.
We additionally found that D2L mRNA levels positively correlated with expression of the cocaine sensitized response (Fig. 2B; r = 0.68, p < 0.01, Pearson correlation), in line with other studies that have found enhanced D2R agonist-induced psychomotor activity following withdrawal from repeated amphetamine20 and in rats self-administering cocaine21,22 and is in agreement with D2L receptors as important mediators of striatal plasticity.15 In line with our findings of a lack of a role of VTA Ca v 1.3 channels or ERK2 in mediating changes in S845 P-GluA1 in the dStr, we found no role of either molecule in the VTA on levels of D2L mRNA (Fig. 2C and D). SIRNA-mediated KD of Ca v 1.3 (Fig. 2C) or ERK2 (Fig. 2D) in the VTA did not alter levels of D2L mRNA in the dStr compared with control siRNA microinjected mice.

We next utilized the D2R antagonist, eticlopride, to examine the functional relevance of higher D2L mRNA on S845 P-GluA1 levels. Blocking D2R's with eticlopride has been shown to increase S845 P-GluA1 levels;19 thus, we hypothesized that eticlopride treatment should result in higher levels of S845 P-GluA1 in the dStr of cocaine pre-exposed mice compared with saline pre-exposed mice, reflective of higher D2L levels. Saline and cocaine pre-exposed C57BL/6 mice were treated with eticlopride (0.2 mg/kg, i.p.) 21 d following the last cocaine injection (Fig. 2E). Consistent with our hypothesis eticlopride treatment resulted in significantly higher levels of S845 P-GluA1 in the dStr of cocaine pre-exposed mice compared with saline pre-exposed mice, reflective of higher D2L levels. We also examined phosphorylation changes of downstream D2R targets including CREB, DARPP-32, Akt and GSK3β24,25 that have been implicated in cocaine’s actions.11,16,17 Ser 133 P-CREB (Fig. 3A), Thr 34 P-DARPP-32 (Fig. 3B) and Thr 308 P-Akt (Fig. 3C) were significantly lower in the striatum of cocaine pre-exposed Ca v 1.3 WT mice but not Ca v 1.3 KO mice (significant interaction, treatment x genotype, Ser 133 P-CREB: F1, 34 = 12.48; p < 0.001; Thr 34 P-DARPP-32: F1, 34 = 30.49; p < 0.0001; Thr 308 P-Akt: F1, 34 = 15.31; p < 0.001) while Thr 75 P-DARPP-32 (Fig. 3D) and Ser 9 P-GSK3β (Fig. 3E), a molecule inhibited by Akt, were significantly higher in Ca v 1.3 WT but not KO mice (significant interaction, treatment x genotype, Thr 75 P-DARPP-32: F1, 34 = 27.39; p < 0.001; Ser 9 P-GSK3β: F1, 34 = 3.66; p < 0.01). Our findings of lower levels of Ser 133 P-CREB and Thr 34 P-DARPP-32, both PKA sites, in the dStr of cocaine pre-exposed mice that have higher levels of D2R's is consistent with D2 inhibiting PKA.26 Furthermore, the presence of higher levels of Thr 75 P-DARPP-32, a form that converts DARPP-32 into a PKA inhibitor,29 additionally supports our finding of lower levels of Ser 133 P-CREB, Thr 34 P-DARPP-32 and Ser 845 P-GluA1. Our finding of lower levels of Thr 308 P-Akt and higher levels of Ser 9 P-GSK3β are in line with D2 receptors inactivating Akt via dephosphorylation at this particular threonine residue, which would increase Ser 9 GSK-3 phosphorylation30 and the involvement of the D2/Akt/GSK pathway in several DA-associated behaviors31 and cocaine sensitization.32

![Figure 3. Repeated cocaine-induced change in phosphorylation of downstream D2 receptor targets are mediated by Ca v 1.3 channels.](image)

**Figure 3.** Repeated cocaine-induced change in phosphorylation of downstream D2 receptor targets are mediated by Ca v 1.3 channels. 

(A-E) Ser 133 P-CREB (A), Thr 34 P-DARPP-32 (B) and Thr 308 P-Akt (D) were significantly lower whereas Thr 75 P-DARPP-32 (D) and Ser 9 P-GSK3β (E) were significantly higher in the striatum of cocaine pre-exposed Ca v 1.3 WT mice compared with Ca v 1.3 KO mice when examined 21 d following cocaine withdrawal. *p < 0.05 vs. sal. n = 8–12/treatment. Data represent the mean ± SEM.

**Conclusion**

Here we demonstrate that repeated cocaine causes a non-VTA Ca v 1.3-dependent recruitment of the D2L signaling pathway in the striatum following extended withdrawal, which decreases basal S845 P-GluA1 and cell surface GluA1 levels. This is in contrast to the VTA Ca v 1.3-dependent recruitment of the Ca v 1.2 signaling pathway in the NAc that has no effect on the basal increase in S845 P-GluA1 and cell surface GluA1 levels that we have recently identified, further elucidating the divergent molecular mechanisms utilized by interconnected regions within addiction circuitry to mediate reward-related behavior.
Materials and Methods

Animals. Male C57BL/6 mice (Charles River Laboratories), Cav1.3 wild-type (WT) and knockout mice (KO), 17 Cav1.2 dihydropyridine (DHP)-insensitive mice 18 and CN5-specific Cav1.3 WT and KO mice 19 generated on the C57BL/6 background were 9-10 weeks of age at the start of all experiments. Mice were provided food and water ad libitum. Animals were maintained on a 12 h light/dark cycle (7:00 a.m. to 7:00 p.m.). All procedures were conducted in accordance with the Massachusetts General Hospital Subcommittee on Research Animal Care and the Weill Cornell Medical College Institutional Animal Care and Use Committee rules.

Reagents. Cocaine HCl, nifedipine and eticlopride were obtained from Sigma-Aldrich. Cocaine and eticlopride were dissolved in 0.9% saline and nifedipine was dissolved in 0.9% saline containing 1.5% DMSO and 1.5% Tween-80. Anti-rabbit Ser 831 P-GluA1 and Ser 845 P-GluA1 were obtained from Abcam. Anti-rabbit GluA1, GluA2, Ser 133 P-CREB, CREB, and CREB were obtained from Millipore. Anti-rabbit Thr 34 and Thr 75 P-DARPP-32, DARPP-32, Thr 308 P-Akt, Akt, Ser 9 P-GSK3β and GSK3β antibodies were obtained from Cell Signaling. Goat anti-rabbit and horse anti-mouse secondary antibodies were obtained from Vector Laboratories.

Psychomotor sensitization protocol. Cocaine psychomotor sensitization was performed as previously described in Giordano et al. (2010). Briefly, mice were habituated to open-field locomotor activity chambers (Med Associates Inc.) for 30 min. Mice were then administered saline or cocaine (15 mg/kg, i.p.) once a day for five days (Day 1-5) and locomotor activity was measured for 30 min on each testing day. Following a 21 d drug-free period, mice were challenged with saline and cocaine (15 mg/kg, i.p.) and locomotor activity measured for 30 min.

Immunoblot analysis. Immunoblotting was performed as previously described in Schierberl et al. 11 Bilateral striatal tissue punches spanning approximately 1.7–1.2 mm A/P relative to Bregma (Paxinos and Franklin, 2004), 19 were obtained with a 17-gauge stainless steel styler in a cryostat. Twenty to 40 µg of proteins were separated on a 10% SDS-polyacrylamide gel and run at 100 V constant voltage. Gels were processed for GluA1 (1:850) and GluA2 (1:1000) immunoblot analysis.

Quantitative real-time PCR (qPCR). For quantitation of mRNA levels, RNA was isolated from striatum tissue punches as described in Schierberl et al. Amplification was performed for 40 cycles (95°C for 15 sec, 60°C for 30 sec, 72°C for 30 sec, extension 72°C for 10 min). For D2L and D2S mRNA detection, D2L- and D2S-specific primers (D2L-specific forward primer, 5'-CACCACCACTCAAGGATGCTGCCCG-3' and reverse primer common to D2L and D2S, 5'-GGTGCTATGTAGACC-GATGAGCAGGA-3') as published in Giordano et al. were used. D1 and D3 mRNA was detected using D1- and D3-specific primers (QuantiTect Primer assay D1, QT00263396 and D3 QT00170527; Qiagen). Cycle threshold (Ct) values for all genes were normalized to the housekeeping gene β-actin. Each experiment was performed in triplicate and values were averaged. For mRNA data analysis, the ΔCt method was used as previously described in Schierberl et al. To obtain nanogram (ng) values of D2L mRNA levels used for correlation analysis in Figure 2B, the standard curve method was used as published in Giordano et al.

Cav1.3 and ERK2 knockdown in the ventral tegmental area. Adenovirally infected vector (AAV) expressing Cav1.3 siRNA or ERK2 siRNA was utilized to knockdown Cav1.3 or ERK2 in the VTA (~3.4–3.5 mm posterior to Bregma and ±0.53 mm lateral to the sagittal suture based on Paxinos and Franklin, and as described in Schierberl et al. 11) A 26-gauge Hamilton syringe was used to deliver 0.5 µl of virus expressing either Cav1.3 siRNA, ERK2 siRNA or scrambled control siRNA into each hemisphere of the VTA at a rate of 0.1 µl/min. Mice were allowed a 3 week period for maximal Cav1.3 and ERK2 knockdown.

Injection placement was confirmed by detection of green fluorescent protein (GFP) by fluorescent immunohistochemistry.

Statistical analysis. For immunoblot analysis, optical density values were used to calculate percentage fold change compared with control group (set to 100%). For qPCR, percentage fold change in mRNA levels was used. Data was analyzed by one-way ANOVA followed by Bonferroni-Dunn post hoc test. Staview 4.5 software (SAS Institute Inc.) was used for all statistics.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

This work was supported by NIDA Grants K01 DA14057 (A.M.R.), R21 DA023686 (A.M.R.) and DA007274-19 (K.S.), Austrian Science Fund P20670 (J.S.) and Deutsche Forschungsgemeinschaft (F.H. and S.M.).
References

1. Everitt BJ, Robbins TW. Neural neural systems of reinforce-

2. Håkansson K, Galdi S, Hendrick J, Snyder G, Greengard P. The role of DARPP-32 in

3. Nestler EJ. Molecular neurobiology of addiction. Am J

4. Tai H, Ong KH, Tham KH, Lim JT, Ng SP, et al. The role of vascular endothelial growth factor (VEGF) in

5. Biedenbender LA, Nishi A, Fisone G, Girault JA, Greengard P. The role of DARPP-32 in

6. Svenningsson P, Nishi A, Fisone G, Girault JA, Greengard P. Dopamine D2 receptors. J Neurosci

7. Nairn AC, Allen PB, Fienberg AA, Valle CG, Huganir RL, et al. Phosphorylation of DARPP-32 by D2 receptors in

8. Galiñanes GL, Heng LJ, et al. Alterations in AMPA

9. Beaulieu JM, Gainetdinov RR, Caron MG. The Akt-

10. Li Y, Cui J, Zhou X, Zhang J, et al. Congenital deafness and sinoatrial node dysfunction in mice lacking class D L-type Ca2+

11. Galiñanes GL, Heng LJ, et al. Alterations in AMPA

12. Beaulieu JM, Gainetdinov RR, Caron MG. The Akt-

13. Galiñanes GL, Heng LJ, et al. Alterations in AMPA

14. Borgkvist A, Fisone G. Psychoactive drugs and

15. Snyder GL, Allen PB, Fienberg AA, Valle CG, Huganir RL, et al. Phosphorylation of DARPP-32 by D2 receptors in

16. Belin D, Everitt BJ. Cocaine seeking habit depends on
dopaminergic D2 receptor signaling. J Neurosci 2004; 24:8214-

17. Nestler EJ. Molecular neurobiology of addiction. Am J

18. Belin D, Everitt BJ. Cocaine seeking habit depends upon dopamine-dependent serial connectivity linking the ventral with the dorsal striatum. Neuron 2003; 37:43-51. PMID:12519497; http://dx.doi.
google.com/10.1016/S0896-6273(03)00139-4

19. Håkansson K, Galdi S, Hendrick J, Snyder G, Greengard P. The role of DARPP-32 in

20. Born D, Everitt BJ. Cocaine seeking habit depends upon dopamine-dependent serial connectivity linking the ventral with the dorsal striatum. Neuron 2003; 37:43-51. PMID:12519497; http://dx.doi.
google.com/10.1016/S0896-6273(03)00139-4

21. De Vries TJ, Schoffelmeer AN, Binnekade R, Raasø H, Valverde F, et al. Role of brain-derived neurotrophic factor in firing rate and variability of striatal medium spiny neurons. J Physiol 2002; 544.269-96; PMID:12458060; http://dx.doi.org/10.1111/j.1469-7793.2002.tb06897.x

22. Thiriot S, Labouesse M, Venance F, Leclerc A, Revuelta C, et al. The role of DARPP-32 in the regulation of Akt activation and activity of PKA and PKC in striatal neurons. J Neurosci 2004; 24:5128-37. PMID:15274569; http://dx.doi.org/10.1523/JNEUROSCI.1277-04.2004

23. Cottone D, Uddin A, Cost C, Pucillo R, Ehrs E, Verkaik G, et al. Choline:indispensable protein corollary long-term potentiation by targeting GSK-3. Neurobiol Dis 2007; 26:129-37. PMID:17154395; http://dx.doi.org/10.1016/j.nbd.2006.04.013

24. Beaulieu JM, Gainetdinov RR, Caron MG. The Akt-

25. Svenningsson P, Nishi A, Fisone G, Girault JA, Greengard P. Dopamine D2 receptors. J Neurosci

26. Rajadhyaksha AM, Kosofsky BE. Psychostimulants, L-type calcium channels, brain, and phosphatase. Neuroscientist 2005; 11:494-502. PMID:16151699; http://dx.doi.org/10.1177/1073858405278236

27. Nair AC, Svenningsson P, Nishi A, Fisone G, Greengard P. The role of DARPP-32 in the actions of drugs of abuse. Neuropharmacology 2006; 51:697-741; http://dx.doi.org/10.1016/j.neuropharm.2006.04.010

28. Ricciardi M, Jr. SO, Sundquist M, Soderberg C, Teda S. Regulation of psychostimulant-induced signaling and gene expression in the nucleus accumbens. J Neurochem 2008; 106:169-49. PMID:18221178; http://dx.doi.org/10.1111/j.1471-4159.2008.05245.x

29. Seid BJ, Kubais PE. Opposing roles for D1 and D2 dopamine receptors in effects of AMPD from

30. Bibb JA, Allen PB, Fienberg A, Yu Y, Meissner I, Krasne A, et al. Phosphorylation of DARPP-32 by Gb alpha5 mediates dopaminergic signaling in neurons. Nature 2001; 409:560-8. PMID:11407323; http://dx.doi.org/10.1038/nn1579

31. Jian Y, Seid BJ, Allen PB, Fienberg A, Yu Y, Meissner I, Krasne A, et al. Phosphorylation of DARPP-32 by Gb alpha5 mediates dopaminergic signaling in neurons. Nature 2001; 409:560-8. PMID:11407323; http://dx.doi.org/10.1038/nn1579

32. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Caron MG, Gainetdinov RR. The Akt-signaling cascade in the actions of dopamine. J Neurosci 2005; 25:4454-65; PMID:15811707; http://dx.doi.org/10.1523/JNEUROSCI.4599-05.2005

33. Miller JS, Tallarida RJ, Unterwald EM. Cocaine-induced hyperactivity and sensitization are dependent on GSK3. Neuropharmacology 2005; 51:165-173; PMID:15633426; http://dx.doi.org/10.1016/j.neuropharm.2005.01.012

34. Raven A, Timmerman TD, Marlon J, Lebon R, Gandolfini RR, Caron MG. A kinetin-like compound mediates dopaminergic neurotransmission and behavioral effects. Cell 2002; 107:227-38; PMID:12013474; http://dx.doi.org/10.1016/S0092-8674(02)00818-1

35. Platzer J, Engel J, Schrott-Fischer A, Stephan K, Bova G, et al. Mammalian target of rapamycin: role in synaptic plasticity and spatial memory. J Neurosci 2004; 24:9443-53; PMID:15273810; http://dx.doi.org/10.1523/JNEUROSCI.2016-2004.2004

36. Galiñanes GL, Heng LJ, et al. Alterations in AMPA

37. Paxinos G, Franklin KBJ. The rat brain in stereotaxic coordinates. 2nd ed. Academic Press. 2004: Second Edition ed2004: Academic

38. Catecholamines. The rat brain in stereotaxic coordinates. 2nd ed. Academic Press. 2004: Second Edition ed2004: Academic Press.